Trevi Therapeutics, Inc. TRVI Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount at other companies
Other financials
Where this comes from
Reported directly by Trevi Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance.
The official record: Trevi Therapeutics, Inc.’s 10-K, filed March 17, 2026, on SEC EDGAR. View the filing →
Ask your AI about Trevi Therapeutics, Inc.'s effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Trevi Therapeutics, Inc.'s effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount?
- Trevi Therapeutics, Inc. (TRVI) reported effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount of $2.24M in Q4 2025.
- How has Trevi Therapeutics, Inc.'s effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount changed year-over-year?
- Trevi Therapeutics, Inc.'s effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount decreased by 13.5% year-over-year, from $2.59M to $2.24M.
- What does effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount mean?
- This metric measures the absolute dollar impact of changes in the valuation allowance for deferred tax assets on the income tax reconciliation. It reflects management's assessment of the likelihood that the company will generate sufficient future taxable income to realize its deferred tax assets. A significant change often signals shifts in the company's long-term profitability outlook.